AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30608444
Drug: OSTAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSTAP block with 40 mL of 0.375% bupivacaine
Trial: 30608444
Drug: Sham group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham group with 40 mL of 0.9% saline
Trial: 26643786
Drug: Topical methyl
RxNorm normalized name: methylal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical methyl aminolevulinate (MAL) and daylight
Trial: 21730016
Drug: Tiagabine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (4 mg, 8 mg, 12 mg)
Trial: 15850603
Drug: Estrogen (conjugated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen (conjugated equine estrogen [CEE] 0.625 mg)
Trial: 10096309
Drug: Alcohol (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (blood alcohol concentration mean = .08 mg%)
Trial: 7635769
Drug: Treatment duration
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment duration < 55 days
Trial: 7635769
Drug: Treatment duration
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment duration >= 55 days
Trial: 7635769
Drug: Stage IB/IIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage IB/IIA treatment duration < 55 days
Trial: 7635769
Drug: Stage IB/IIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage IB/IIA treatment duration >= 55 days
Trial: 7635769
Drug: Stage III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage III treatment duration < 55 days
Trial: 7635769
Drug: Stage IIB
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage IIB treatment duration >= 55 days
Trial: 2144391
Drug: Intramuscular vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccination (20 micrograms)
Trial: 2144391
Drug: Intradermal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccination (2 micrograms)
Trial: 625669
Drug: Phenoxybenzamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenoxybenzamine treatment after urinary retention
Trial: 28019652
Drug: Reduction in
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction in WHO risk drinking levels during treatment
Trial: 25212749
Drug: Sertraline (200mg/day)
RxNorm normalized name: sertraline 200 MG
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline (200mg/day) with DRD4 <7 repeats
Trial: 17265490
Drug: Glucosamine sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine sulfate 1,500 mg once daily (n = 106)
Trial: 15354322
Drug: Conjugated linoleic
RxNorm normalized name: CONJUGATED LINOLEIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated linoleic acid (CLA) 6 g/day
Trial: 17214993
Drug: AGI‐1067 280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGI‐1067 280 mg qd for 12 months after PCI
Trial: 15470797
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg naloxone administered intravenously
Trial: 3085789
Drug: Sodium etidronate
RxNorm normalized name: Sodium etidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium etidronate 20 mg/kg/day for two and four weeks
Trial: 3085789
Drug: Sodium etidronate
RxNorm normalized name: Sodium etidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium etidronate 20 mg/kg/day for four weeks
Trial: 3085789
Drug: Sodium etidronate
RxNorm normalized name: Sodium etidronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium etidronate 20 mg/kg/day for two weeks
Trial: 11578893
Drug: Air-O(2) mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air-O(2) mixture with FGF 0.5 L/min (4/1 ratio)
Trial: 11578893
Drug: Air-O(2) mixtures
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air-O(2) mixtures with FGF < or = 2 L/min
Trial: 26516803
Drug: Ultrasound-guided single-injection
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided single-injection infraclavicular block
Trial: 26516803
Drug: Ultrasound-guided double-injection
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided double-injection axillary block
Trial: 24619917
Drug: Pradigastat co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradigastat co-administered with digoxin
Trial: 24619917
Drug: Pradigastat co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pradigastat co-administered with warfarin
Trial: 18068064
Drug: Fenoldopam infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoldopam infusion (0.1 microg/kg/min)
Trial: 15654790
Drug: Alosetron (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron (0.5 mg, 1.0 mg, 2.0 mg, 4.0 mg)
Trial: 25391382
Drug: Antidementia drugs
RxNorm normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidementia drugs (memantine, donepezil, rivastigmine, galantamine)
Trial: 25391382
Drug: Antidementia drugs
RxNorm normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidementia drugs
Trial: 11330505
Drug: Intact insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intact insulin
Trial: 31919502
Drug: Metabolic pathway
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metabolic pathway glycine, serine, and threonine metabolism
Trial: 25416584
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of standard rehabilitation interventions and scapulothoracic joint control training exercises
Trial: 16360199
Drug: Low-dose Z-100
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Z-100 (0.2 microg)
Trial: 16360199
Drug: High-dose Z-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Z-100 (40 microg)
Trial: 10378565
Drug: Kinetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinetic therapy (KT) combined with mechanical percussion (P) using a KT system (Triadyne Kinetic Therapy System; KCI; San Antonio, TX)
Trial: 8777824
Drug: Hyperglycaemia (8.5‐10.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemia (8.5‐10.5 mmol/l)
Trial: 1380475
Drug: Somatostatin infusion
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin infusion during ERCP
Trial: 31054101
Drug: Chemotherapy (CHT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CHT) - temozolomide 200 mg/m2/day for 5 days every 28 days
Trial: 25826322
Drug: RGN‐259 (0.1%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RGN‐259 (0.1%) eye drops, 6 times daily for 28 days
Trial: 21422759
Drug: Human tissue
RxNorm normalized name: Recombinant human tissue kallikrein-1
DrugBank: Recombinant human kallikrein-1 (DB19232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human tissue kallikrein with conventional treatment over 12-14 days
Trial: 8562742
Drug: Zaldaride maleate
RxNorm normalized name: maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaldaride maleate (20 mg four times per day)
Trial: 2642629
Drug: Oral milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral milrinone
Trial: 30238650
Drug: Self-management intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-management intervention using teach-back, including individual teaching session, heart failure booklet, weighing scales, diary for daily weight, follow-up phone call 2 weeks after discharge.
Trial: 25446376
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus sorafenib (1000 mg/m2 once weekly for 7 weeks + 1 week rest, then once every 3 weeks + 1 week rest)
Trial: 20237316
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg subcutaneously and 75 mg of aspirin orally once daily along with intense pregnancy surveillance
Trial: 31373112
Drug: Topical Citrullus
RxNorm normalized name: Citrullus colocynthis fruit extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Citrullus colocynthis oil
Trial: 27502326
Drug: Fimasartan 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fimasartan 60 mg
Trial: 22306735
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with STAMP-V (carboplatin, thiotepa, and cyclophosphamide), ACT (doxorubicin, paclitaxel, and cyclophosphamide), or tandem melphalan and STAMP-V
Trial: 17763111
Drug: Active bupropion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active bupropion and active 4‐mg gum (AA)
Trial: 11598360
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no hormonal pre‐medication)
Trial: 8682138
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of atenolol and nifedipine
Trial: 25545026
Drug: Oral fingolimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fingolimod 0.5mg once daily
Trial: 25545026
Drug: Oral fingolimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fingolimod 1.25mg once daily
Trial: 25545026
Drug: Intramuscular interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon β‐1a (IFNβ‐1a IM) 30 μg/mL once weekly
Trial: 19248104
Drug: 0.9% MQX-503
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% MQX-503 gel
Trial: 17087689
Drug: Occupational/Physical Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational/Physical Therapy (OT/PT) intervention delivered via teletechnology or in-home visits
Trial: 8378244
Drug: Remoxipride oral
RxNorm normalized name: remoxipride Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride oral suspension (100 mg dose)
Trial: 24664172
Drug: Valacyclovir 1
RxNorm normalized name: valacyclovir 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 1 g orally each day for 2 months
Trial: 15386328
Drug: Invasive breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive breast cancer patients with oestrogen receptor-negative tumours
Trial: 2493710
Drug: Midazolam 0.2
RxNorm normalized name: midazolam 0.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.2 mg/kg, vecuronium bromide 0.1 mg/kg intravenously, and 3 vol.% isoflurane in oxygen for induction; nitrous oxide 66% in oxygen and 0.9 vol.% isoflurane for maintenance
Trial: 30394344
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg of rectal misoprostol before cesarean section
Trial: 30394344
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg of rectal misoprostol after cesarean section
Trial: 19922671
Drug: Insulin Resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin Resistance (IR) assessed by HOMA-IR
Trial: 9146851
Drug: Transdermal delivery
RxNorm normalized name: nitroglycerin 5 mg in 1 d TRANSDERMAL PATCH [Nitroglycerin Transdermal Delivery System]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal delivery of acetylcholine via iontophoresis (150 microA for 40 s) at various sites in the forearm and hand
Trial: 2834115
Drug: Heparin pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin pretreatment (5000 IU IV before exercise)
Trial: 27664548
Drug: Cognitive-behavioral group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral group therapy (CBGT) with 12 sessions, two involving family members
Trial: 23374199
Drug: Strain-counterstrain treatment
RxNorm normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strain-counterstrain treatment
Trial: 9186253
Drug: Vigabatrin (3,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vigabatrin (3,000 mg daily for 4 weeks)
Trial: 27084855
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics (Control group)
Trial: 29685693
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg daily for 15 days
Trial: 22453707
Drug: Link Samahan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Link Samahan® (one sachet daily in hot water)
Trial: 18426595
Drug: IFN beta‐1a,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN beta‐1a, 44 mcg subcutaneously (sc) three times weekly (tiw)
Trial: 18426595
Drug: IFN beta‐1a,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN beta‐1a, 30 mcg intramuscularly (im) once weekly (qw)
Trial: 11037895
Drug: Diacerein 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacerein 100 mg/day (50 mg twice daily)
Trial: 11037895
Drug: Diacerein 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diacerein 150 mg/day
Trial: 8803379
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine infusion (IVL) 2 mg/kg
Trial: 8803379
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine infusion (IVL) 5 mg/kg
Trial: 8887580
Drug: Oral mexiletine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mexiletine
Trial: 1730902
Drug: Heat-inactivated anti-HIV
RxNorm normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-inactivated anti-HIV antibody-rich plasma (7 transfusions every 2 weeks)
Trial: 1730902
Drug: Heat-inactivated anti-HIV
RxNorm normalized name: INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-inactivated anti-HIV antibody-rich plasma
Trial: 18495737
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of albendazole daily for 8 days
Trial: 9292380
Drug: Home-based multisystemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based multisystemic therapy
Trial: 1750591
Drug: Protamine titration
RxNorm normalized name: protamines
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protamine titration using the Hemochron system
Trial: 1750591
Drug: Empirical dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical dose protocol
Trial: 29199654
Drug: Radiotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy and concurrent cisplatin infusion (Group B)
Trial: 18089874
Drug: Cisplatin 80
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 80 mg/m2 intravenously on day 1 without raltitrexed
Trial: 15336467
Drug: Controlled-release oxybutynin
RxNorm normalized name: oxybutynin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release oxybutynin (15 mg/d, adjusted in 5 mg/d increments)
Trial: 11876710
Drug: Omeprazole, 20
RxNorm normalized name: Omeprazole, 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 20 mg/day for 2 weeks
Trial: 11876710
Drug: Pantoprazole, 40
RxNorm normalized name: Pantoprazole, 40 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole, 40 mg/day for 2 weeks
Trial: 9632571
Drug: Conjugates and
RxNorm normalized name: conjugated estrogens and bazedoxifene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugates and cellular vaccine
Trial: 3311661
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg cisapride
Trial: 6111126
Drug: Triazolam (Halcion)
RxNorm normalized name: Triazolam
DrugBank: Triazolam (DB00897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triazolam (Halcion) 0.25 mg
Trial: 26479162
Drug: Oxycodone/Acetaminophen (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone/Acetaminophen (5 mg/325 mg)
Trial: 26176973
Drug: Codeine/Acetaminophen (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine/Acetaminophen (30 mg/300 mg)
Trial: 21787184
Drug: Mannitol (MTL)
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol (MTL) 20% (4 mL/kg)
Trial: 21787184
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (HTS) 7.5% (2 mL/kg)
Trial: 17592080
Drug: L-arginine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (3 g/d)
Trial: 15106410
Drug: omeprasol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprasol (40 mg/day) and de‐nol (480 mg/day)
Trial: 15106410
Drug: omeprasol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprasol (40 mg/day)
Trial: 9613647
Drug: Intranasally administered
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasally administered immunoglobulin (mainly immunoglobulin A), nasal spray, twice daily for 8 weeks
Trial: 26473751
Drug: VX-509 100
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VX-509 100 mg/day
Trial: 26473751
Drug: VX-509 200
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VX-509 200 mg/day
Trial: 24196971
Drug: TENS and
RxNorm normalized name: ECAMSULE 39.6 mg in 1 mL / OCTINOXATE 67.4 mg in 1 mL / TITANIUM DIOXIDE 32.8 mg in 1 mL TOPICAL CREAM [KIEHLS ULTRA LIGHT DAILY UV DEFENSE TONE UP SPF 50 ANTI POLLUTION INSTANTLY BRIGHTENS AND HYDRATES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TENS and local injection of cobalamin
Trial: 24196971
Drug: TENS with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TENS with a combination of cobalamin and lidocaine
Trial: 24196971
Drug: TENS and
RxNorm normalized name: ECAMSULE 39.6 mg in 1 mL / OCTINOXATE 67.4 mg in 1 mL / TITANIUM DIOXIDE 32.8 mg in 1 mL TOPICAL CREAM [KIEHLS ULTRA LIGHT DAILY UV DEFENSE TONE UP SPF 50 ANTI POLLUTION INSTANTLY BRIGHTENS AND HYDRATES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TENS and local injection of lidocaine
Trial: 16417774
Drug: Suogudan Granule
RxNorm normalized name: REHMANNIA GLUTINOSA WHOLE 3 g ORAL TABLET [SUODAN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suogudan Granule (SGDG) 6 g orally, thrice a day for 6 weeks
Trial: 1923078
Drug: Amoxicillin‐potassium clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin‐potassium clavulanate
Trial: 25733639
Drug: High flavanol
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flavanol (HF) cocoa flavanols (993 mg)
Trial: 25733639
Drug: Intermediate flavanol
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate flavanol (IF) cocoa flavanols (520 mg)
Trial: 25733639
Drug: Low flavanol
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low flavanol (LF) cocoa flavanols (48 mg)
Trial: 24393375
Drug: FAIM2-rs7138803 polymorphism
RxNorm normalized name: ANGELICA POLYMORPHA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAIM2-rs7138803 polymorphism (AA vs G-carriers)
Trial: 24393375
Drug: FAIM2-rs7138803 polymorphism
RxNorm normalized name: ANGELICA POLYMORPHA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAIM2-rs7138803 polymorphism (AA vs G-carriers) in type-2 diabetic subjects
Trial: 2104036
Drug: Diet 1
RxNorm normalized name: Phendiet 105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet 1 (D1, n = 5) - 450‐550 kcal/d, protein at 1.5 g/kg IBW, less than 10 g carbohydrate (CHO)
Trial: 2104036
Drug: Diet 2
RxNorm normalized name: gluc-msm-vit C-FA-mang-diet 29 125 mg-37.5 mg-25 mg-500 mcg-1.25 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet 2 (D2, n = 5) - 420 kcal/d formula, providing 70 g (1.2 g/kg IBW) protein and 30 g CHO
Trial: 7467379
Drug: Droperidol (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (higher dosage)
Trial: 17227743
Drug: Homeopathic Arnica
RxNorm normalized name: ARNICA MONTANA WHOLE 6 [hp_X] ORAL LOZENGE [Homeopathic Arnica Drops]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic Arnica 30c, 2 tablets 6 times on the first post-operative day and then 2 tablets twice a day for the next 7 days
Trial: 17227743
Drug: Identical placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo, 2 tablets 6 times on the first post-operative day and then 2 tablets twice a day for the next 7 days
Trial: 15155712
Drug: VIP at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VIP at doses ranging from 25 to 800 pmol
Trial: 15155712
Drug: Inhibition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibition of H1 receptors